Transcriptomics

Dataset Information

0

Discordant cellular response to pre-surgical letrozole in bilateral synchronous ER+ breast cancers with a KRAS mutation or FGFR1 gene amplification


ABSTRACT: This clinical case resulted from an ongoing trial at Vanderbilt University and abroad where ER+ breast cancer patients are administered 2-3 weeks of aromatase inhibitor therapy leading up to definitive surgical resection of the tumor. In this case, we describe a study patient presenting with bilateral primary ER+ breast tumors. Short term hormonal therapy substantially reduced proliferation in one tumor, while the second was essentially unchanged. Extensive molecular and genetic workup of the two tumors yielded divergent lesions in the two tumors; an activating KRAS mutation in the responsive tumor, and an amplification of the FGFR1 locus in the treatment-refractory tumor.

ORGANISM(S): Homo sapiens

PROVIDER: GSE39387 | GEO | 2012/07/17

SECONDARY ACCESSION(S): PRJNA170759

REPOSITORIES: GEO

Dataset's files

Source:
Action DRS
Other
Items per page:
1 - 1 of 1

Similar Datasets

2012-07-16 | E-GEOD-39387 | biostudies-arrayexpress
| S-EPMC3682668 | biostudies-literature
| S-ECPF-GEOD-39387 | biostudies-other
2020-07-01 | GSE145325 | GEO
2016-12-31 | GSE77626 | GEO
| S-EPMC9938400 | biostudies-literature
2009-08-15 | GSE10281 | GEO
2017-06-12 | GSE85754 | GEO
2019-12-19 | GSE142308 | GEO
| S-EPMC8024796 | biostudies-literature